For more than two decades, menopausal women have been undertreated - not because effective therapies were unavailable, but because flawed science communication led them to be perceived as unsafe. The evidence has long suggested otherwise. Clinical practice is only now beginning to realign with that reality.
The inflection point was the 2002 Women’s Health Initiative (WHI) trial. Its findings - increased risks of breast cancer, venous thromboembolism, coronary heart disease, and stroke associated with hormone replacement therapy (HRT) - led to a rapid and sustained decline in prescribing. However, the issue was not the data itself, but its interpretation. Risks were overstated, removed from their clinical context, and generalised to populations far younger and healthier than those studied. Subsequent analyses revealed a far more nuanced risk profile, but by then the narrative had become firmly established.
Regulatory action reinforced this shift. The FDA’s boxed warning, the most prominent safety warning applied to prescription medications, was extended broadly across HRT products and remained in place for over twenty years. Its impact was profound. Prescribing declined, clinician confidence eroded, and clinical experience diminished. A generation of clinicians entered practice with limited training in menopause management, while many women continued to experience symptoms that were, in fact, highly treatable.
This context is critical because HRT is not a marginal intervention. While it remains the most effective treatment for vasomotor symptoms, its clinical relevance extends considerably further.
Oestrogen plays a central role in bone metabolism. Its decline at menopause accelerates bone loss, substantially increasing the risk of osteoporotic fractures. Hip fractures, in particular, are associated with one-year mortality rates of up to 30% and significant long-term morbidity. HRT is among the most effective interventions for reducing this risk, yet fracture prevention remains underemphasised in treatment discussions, rather than being recognised as a primary clinical indication.
Cardiovascular effects are closely linked to the timing of initiation. Evidence indicates that women who commence HRT within ten years of menopause onset or before the age of 60 experience a meaningful reduction in coronary heart disease events, on the order of 30%. This benefit is not observed with later initiation, when established atherosclerosis limits vascular responsiveness to oestrogen. Timing, therefore, is not incidental but central to clinical decision-making.
Hormonal changes also have important implications for mental health. In some women, new-onset depression and anxiety during the perimenopausal period are hormonally mediated. Oestrogen influences key neurotransmitter systems, and its decline can contribute directly to mood disturbance. In such cases, conventional antidepressant therapy may be insufficient. Consideration of the hormonal context is therefore essential, and HRT may represent a more appropriate first-line intervention.
Urogenital syndrome of menopause is similarly under-recognised despite its high prevalence and progressive nature. Symptoms such as vaginal atrophy, dyspareunia, urinary urgency, and recurrent urinary tract infections are common but frequently underreported and underdiagnosed. Local oestrogen therapies are highly effective, associated with minimal systemic absorption, and appropriate for the majority of postmenopausal women. In older patients, preventing recurrent infections is not solely a matter of quality of life but of patient safety.
These benefits must be balanced against known risks. Combined oestrogen–progestin therapy is associated with a small, duration-dependent increase in breast cancer risk, which diminishes after cessation. Oral formulations are linked to an increased risk of venous thromboembolism, whereas transdermal preparations substantially mitigate this effect. These risks are real but are also modifiable and highly dependent on formulation, route of administration, and patient selection. Individualised prescribing is therefore essential.
The FDA’s removal of the boxed warning in early 2026 represents a formal recognition of what the evidence has indicated for some time. Prescribing patterns are beginning to shift, and clinician confidence is gradually returning. However, the objective is not simply increased utilisation. It is the appropriate use of therapy, guided by a clear understanding of both risks and benefits.
Women should not continue to experience untreated symptoms where effective interventions exist. Clinicians should not remain constrained by outdated interpretations of evidence. And menopause care should no longer be defined by a narrative shaped more by miscommunication than by data.